On the promise of artificial intelligence for standardizing radiographic response assessment in gliomas. by Ellingson, Benjamin M
UCLA
UCLA Previously Published Works
Title
On the promise of artificial intelligence for standardizing radiographic response assessment 
in gliomas.
Permalink
https://escholarship.org/uc/item/3d7289nc
Author
Ellingson, Benjamin M
Publication Date
2019-09-06
DOI
10.1093/neuonc/noz162
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
  
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-
Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 
On the promise of artificial intelligence for standardizing radiographic response 
assessment in gliomas  
Benjamin M. Ellingson, Ph.D.1 
1 UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging 
Biomarkers, Department of Radiological Sciences, David Geffen School of e,  
University of California Los Angeles, Los Angeles, CA 90  
 
(Editorial on  
nt of glioma burden: A deep learni  rithm for fully automated 
volumetric and bi-dimen i  rement") 
 
Address Correspondence To:  
Benjamin M. Ellingson, Ph.D. 
Professor of Radiology, Bi  hysics, Bioengineering, and Psychiatry 
Departments of Radiolo  nces and Psychiatry 
David Geffen Sch   e 
University of ia  Los Angeles 
9   lvd, Suite 615 
L   CA 90024 
bellingson@mednet.ucla.edu 
 
 
 
  
 
 
Identification and delineation of tumor burden on MR images is a critical, yet 
challenging, function for clinical care and neuro-oncology research. Changes in tumor burden on 
structural MRI sequences are used as surrogates for efficacy throughout the entire drug 
development pipeline, from initial preclinical evaluations through clinical t   human 
patients. DeepNeuro, the algorithm recently published by Chang et al.1     utomated 
approaches to tumor segmentation (see reviews by Gordillo et al.2    l.3, and Bauer et 
al.4), combined with standardization of image acquisition and g ble interpretation of 
radiographic changes, holds great promise for accurate, re e, efficient, and inexpensive 
tumor segmentation.  
Manual or semi-automated quant   r size by experts using commercial or 
academic tools is highly variable acros  5 and is extremely time consuming, labor 
intensive, inefficient, and expen  ert neuroradiologists in large clinical trials average 
more than 40% adjudicati   which is consistent with adjudication or discrepancy rates 
between radiologists in  or types and between central review compared with local site 
call of progression  Difficulty in determining changes in T2 hyperintense lesions on 
RANO was o  ermined to be the largest reason for adjudication, while changes in contrast 
en  eared less ambiguous, but still relatively difficult. While some investigators 
h  ed volumetric segmentation on T1 subtraction maps may be a way to replace 
blinded, adjudicated central reads10, there remains significant questions as to the reproducibility 
of simple segmentation approaches in the presence of artifacts and generalization of these 
threshold-based segmentation techniques for all relevant components of the tumor (e.g. 
enhancing, necrotic, and non-enhancing disease). Automated segmentation and quantitative 
  
 
response assessment using a large set of post-therapeutic data, as demonstrated by DeepNeuro1, 
has significant potential to reduce these adjudication rates while allowing investigators and 
regulators to evaluate potential changes in various aspects of the tumor biology. 
In addition to standard response assessment, clearly defining regions of interest for both 
T2 hyperintense lesions (e.g. edema and/or non-enhancing tumor) and contrast en  lesions 
on post-contrast T1-weighted images are critical for obtaining advanced im  urements 
(diffusion, perfusion, PET, etc.) within areas of active disease. Thu   gmentation itself 
adds another level of uncertainty beyond the inherent variabilit   d image acquisition 
and post-processing. The use of an automated and standar  umor segmentation algorithm 
like DeepNeuro could conceivably reduce variabilit  i  ced imaging analyses and increase 
repeatability of results across centers and   
Performance of sophisticated alg  e DeepNeuro are going to greatly improve 
through the adaptation and impl n of the standardized brain tumor imaging protocol 
(BTIP)11. Introduced in 2015   sult of a joint meeting between the FDA, NCI, clinical 
scientists, imaging exp  maceutical and biotech companies, clinical trial cooperative 
groups, and patie   oups, BTIP is compliant with ACRIN and EORTC guidelines 
and includes  mum recommended sequences for response assessment using 1.5T and 3T 
M   ince most machine learning algorithms utilize public datasets obtained from 
in  stitutions or trials that may not be BTIP compliant, they are innately designed to 
generalize across a wide range of acquisition parameters and machine settings. By streamlining 
and focusing the range of MR parameters that are acceptable for use in clinical trials, 
performance of automated algorithms will theoretically improve as trials comply with BTIP and 
adapt to less variability in imaging characteristics.   
  
 
 
“ We are drowning in data but starved for wisdom.”  
~ Arianna Huffington, Founder of Huffington Post re: Artificial Intelligence 
More than 200 scientific abstracts, plenary talks, and presentations were devoted to 
artificial intelligence or machine learning at the 2018 Radiologic Society of  America 
(RSNA) annual meeting last year. In radiology, artificial i
approaches are changing the way we schedule patients, acquire  -process images, 
measure tumor size, dictate or interpret changes, and charge  g cal services. While 
DeepNeuro and other techniques with automatic pipelines  omise of reducing ambiguity 
and variability in tumor segmentation, these alg ith   , 
which may be problematic as experts ma    y vetted or trained, may have difficulty 
accurately defining tumor boundaries   gliomas, and/or they may not utilize all 
approaches we know to be usefu   ning active disease (e.g. T1 subtraction maps, subtle 
signal intensity changes on T2 ed images, architectural disruption at the gray-white matter 
boundary, etc.). Addit  ost of the available automated algorithms have been trained 
entirely on treatm   ors5, which is a much simpler problem (i.e. no post-surgical or 
post-therapeu  ges) with no tangible clinical impact. It is more meaningful, and admittedly 
m    try and differentiate changes in tumor during the post-therapeutic setting or 
d  ment with experimental therapeutics. While DeepNeuro may not have not yet 
undergone extensive testing under various therapeutic contexts (e.g. anti-angiogenic or 
immunotherapies), or in challenging tumor types (e.g. gliomatosis cerebri, mixed grade tumors, 
etc.), their attempt to adapt their algorithm to perform an automated response assessment during 
treatment within a clinical trial is a strong, noteworthy step in the right direction. Thus, while 
  
 
promising, artificial intelligence is inherently only as good as the knowledge we are able to 
provide. These algorithms currently cannot generate new wisdom into the intrinsic biology of 
brain tumors, nor can they begin to unravel the true extent of tumor infiltration into the brain. 
Perhaps someday, with the addition of autopsy data, this later goal could become a reality. 
However, just like humans, these new A.I. algorithms have the ability to adapt  ad  arn, and 
-  based on new or improved knowledg   
We are at the dawn of a renaissance in imaging technology i  cology. Artificial 
intelligence-based techniques and approaches for automated re  ssment are going to 
increase in sophistication and complexity in the years and s to come. Investigators and 
regulators should be acutely aware of the limitati    echnology, providing wisdom and 
context to further guide the developmen   ation in both clinical trials and clinical 
care for the benefit of brain tumor patient   
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